ATE219495T1 - Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel - Google Patents

Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel

Info

Publication number
ATE219495T1
ATE219495T1 AT96937702T AT96937702T ATE219495T1 AT E219495 T1 ATE219495 T1 AT E219495T1 AT 96937702 T AT96937702 T AT 96937702T AT 96937702 T AT96937702 T AT 96937702T AT E219495 T1 ATE219495 T1 AT E219495T1
Authority
AT
Austria
Prior art keywords
hypocholesterdenic
azetidinone
drugs
usable
sugar substituted
Prior art date
Application number
AT96937702T
Other languages
English (en)
Inventor
Nathan P Yumibe
Kevin B Alton
Heek Margaret Van
Harry R Davis
Wayne D Vaccaro
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26677904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219495(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE219495T1 publication Critical patent/ATE219495T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96937702T 1995-10-31 1996-10-29 Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel ATE219495T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US818595P 1995-10-31 1995-10-31
US57084795A 1995-12-12 1995-12-12
PCT/US1996/016823 WO1997016455A1 (en) 1995-10-31 1996-10-29 Sugar-substituted 2-azetidinones useful as hypocholesterolemic a gents

Publications (1)

Publication Number Publication Date
ATE219495T1 true ATE219495T1 (de) 2002-07-15

Family

ID=26677904

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937702T ATE219495T1 (de) 1995-10-31 1996-10-29 Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel

Country Status (27)

Country Link
EP (1) EP0877750B1 (de)
JP (2) JP3385031B2 (de)
KR (1) KR100311554B1 (de)
CN (1) CN1103780C (de)
AR (1) AR004701A1 (de)
AT (1) ATE219495T1 (de)
AU (1) AU712158B2 (de)
BR (2) BR9611401B1 (de)
CA (1) CA2235943C (de)
CY (1) CY2353B1 (de)
CZ (1) CZ293957B6 (de)
DE (1) DE69621952T2 (de)
DK (1) DK0877750T3 (de)
ES (1) ES2175141T3 (de)
GE (1) GEP20033006B (de)
HU (1) HU226822B1 (de)
ID (1) ID16177A (de)
IL (1) IL124268A (de)
MX (1) MX9803447A (de)
MY (1) MY114803A (de)
NO (1) NO311692B1 (de)
NZ (1) NZ321766A (de)
PL (1) PL184698B1 (de)
PT (1) PT877750E (de)
SK (1) SK283552B6 (de)
TW (1) TW448181B (de)
WO (1) WO1997016455A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
EP1510521A1 (de) * 2000-12-20 2005-03-02 Schering Corporation Zuckersubstituierte 2-Azetidinone Verwendbar als Hypocholesterdenische Arzneimittel
TR200402758T4 (tr) * 2000-12-20 2004-11-22 Schering Corporation Hipokolesterolemik ajanlar olarak faydalı şekerle ikame edilen 2-azetidinonlar.
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE10064398A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Neue Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU1609702A (en) * 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
US20020147184A1 (en) * 2001-01-26 2002-10-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP4711600B2 (ja) * 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
EA006898B1 (ru) 2001-03-28 2006-04-28 Шеринг Корпорейшн Энантиоселективный синтез промежуточных соединений для получения азетидинонов
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP2005015434A (ja) 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1522541A1 (de) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Neue hypocholesterolemische Verbindungen
WO2005044256A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
JP2008539255A (ja) * 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US9212175B2 (en) 2009-03-06 2015-12-15 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
CA2120221A1 (en) * 1993-04-23 1994-10-24 Allan W. Rey N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
ES2175141T3 (es) 2002-11-16
KR19990067202A (ko) 1999-08-16
CN1205707A (zh) 1999-01-20
NO981950L (no) 1998-06-26
BR9611401A (pt) 1999-01-05
PL327987A1 (en) 1999-01-04
DE69621952T2 (de) 2003-01-16
HK1012507A1 (en) 1999-08-06
CZ293957B6 (cs) 2004-08-18
JP3385031B2 (ja) 2003-03-10
MY114803A (en) 2003-01-31
BR9612998B1 (pt) 2010-03-23
ID16177A (id) 1997-09-11
TW448181B (en) 2001-08-01
BR9611401B1 (pt) 2010-08-10
AR004701A1 (es) 1999-03-10
DK0877750T3 (da) 2002-07-15
CY2353B1 (en) 2004-06-04
PT877750E (pt) 2002-09-30
NO311692B1 (no) 2002-01-07
HU226822B1 (en) 2009-11-30
IL124268A (en) 2005-08-31
GEP20033006B (en) 2003-07-10
EP0877750A1 (de) 1998-11-18
CN1103780C (zh) 2003-03-26
JP2001048895A (ja) 2001-02-20
CA2235943A1 (en) 1997-05-09
CZ129498A3 (cs) 1998-10-14
SK283552B6 (sk) 2003-09-11
SK48398A3 (en) 1998-11-04
CA2235943C (en) 2002-10-01
MX9803447A (es) 1998-09-30
WO1997016455A1 (en) 1997-05-09
NZ321766A (en) 1999-07-29
JPH10512592A (ja) 1998-12-02
HUP9802539A3 (en) 1999-12-28
DE69621952D1 (de) 2002-07-25
HUP9802539A2 (hu) 1998-11-30
NO981950D0 (no) 1998-04-29
AU7517996A (en) 1997-05-22
KR100311554B1 (ko) 2002-06-20
AU712158B2 (en) 1999-10-28
EP0877750B1 (de) 2002-06-19
PL184698B1 (pl) 2002-12-31

Similar Documents

Publication Publication Date Title
ATE219495T1 (de) Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
DE69713284D1 (de) Triazol-Derivate als Arzneimittel
NL300214I2 (nl) Chinazolinederivaten.
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
ATE367150T1 (de) Arzneimittel
IS1903B (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
DE60106489D1 (de) Zuckersubstituierte 2-azetidinone verwendbar als hypocholesterdenische arzneimittel
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
TR199600883A2 (tr) Pürin-6-on türevleri.
TR199600715A2 (tr) Kefalosforin türevleri.
NO960499D0 (no) Antineurodegenerativt virksomme 10-aminoalifatyldibenz[b,fÅoksepiner
DE69628458D1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalceriferol derivate
NL1000487C2 (nl) Oogstmachine.
TR199600064A2 (tr) 4-amino-benzoilguanidin-türevleri.
TR199601018A1 (tr) Farmasötik bilesikler.
NL1000001A1 (nl) Stal.
ES1032571Y (es) Gafa,
NL1000212C2 (nl) Scharniersysteem.
NL1002934C2 (nl) Deur.
IT1276501B1 (it) Via tranviaria.
TR199600311A1 (tr) Pelit sekeri.
ES1030601Y (es) Radiador-convector, perfeccionado.
FI953158A0 (fi) Foerfarande foer biologisk rening av vatten, saerskilt foer minskning av kvaevehalten
ES1031395Y (es) Minicapsula de maquillaje.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification